top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Thomas Ricks Biography and Net Worth

Director of Sensei Biotherapeutics

Tom Ricks has been a member of the Board of Directors since 2015. Mr. Ricks is the former Chief Investment Officer of H&S Ventures LLC, a private investment firm. Prior to taking this position with H&S Ventures, he was Chief Executive Officer of The University of Texas Investment Management Company. Mr. Ricks also served as Vice Chancellor for Asset Management for The University of Texas System and as Executive Director of Finance and Private Investments. He has been a director of Newfield Exploration Company (NYSE:NFX) since 1992 and is Chairman of its Audit Committee. He is a former director of BDM International, DTM Corporation, LifeCell Corporation and Argus Pharmaceuticals. Mr. Ricks also previously served on the Investment Committee of the University of California Foundation, Irvine and previously served on the board of the Ocean Institute. Mr. Ricks holds a B.A. in Economics from Trinity College, an M.B.A. from the University of Chicago.

What is Thomas G. Ricks' net worth?: The estimated net worth of Thomas G. Ricks is at least $115,303.97 as of June 7th, 2022. Mr. Ricks owns 116,269 shares of Sensei Biotherapeutics stock worth more than $115,304 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Ricks may own. Learn More about Thomas G. Ricks' net worth.
How do I contact Thomas G. Ricks?: The corporate mailing address for Mr. Ricks and other Sensei Biotherapeutics executives is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. Sensei Biotherapeutics can also be reached via phone at 240-243-8000 and via email at [email protected]. Learn More on Thomas G. Ricks' contact information.
Has Thomas G. Ricks been buying or selling shares of Sensei Biotherapeutics?: Thomas G. Ricks has not been actively trading shares of Sensei Biotherapeutics during the past quarter. Most recently, on Thursday, December 9th, Thomas G. Ricks bought 20,000 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $6.62 per share, with a total value of $132,400.00. Learn More on Thomas G. Ricks' trading history.
Who are Sensei Biotherapeutics' active insiders?: Sensei Biotherapeutics' insider roster includes James Peyer (Director), Robert Pierce (Insider), and Thomas Ricks (Director). Learn More on Sensei Biotherapeutics' active insiders.
Are insiders buying or selling shares of Sensei Biotherapeutics?: During the last year, Sensei Biotherapeutics insiders bought shares 1 times. They purchased a total of 500 shares worth more than $425.00. During the last year, insiders at the sold shares 1 times. They sold a total of 3,441,661 shares worth more than $5,437,824.38. The most recent insider tranaction occured on September, 11th when CEO John Celebi bought 500 shares worth more than $425.00. Insiders at Sensei Biotherapeutics own 25.5% of the company. Learn More about insider trades at Sensei Biotherapeutics.
Information on this page was last updated on 9/11/2023.

Thomas G. Ricks Insider Trading History at Sensei Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/9/2021	Buy	20,000	$6.62	$132,400.00

Thomas G. Ricks Buying and Selling Activity at Sensei Biotherapeutics

Sensei Biotherapeutics Company Overview

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Today's Range

Now: $0.99

$0.94

$1.04

50 Day Range

MA: $0.96

$0.76

$1.17

2 Week Range

Now: $0.99

$0.51

$1.72

Volume

54,562 shs

Average Volume

64,946 shs

Market Capitalization

$24.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17